Allogeneic blood or bone marrow transplantation is a successful treatment for leukaemia and severe aplastic anaemia (SAA). Graft rejection following transplantation for leukaemia is a rare event but leukaemic relapse may occur at varying rates, depending upon the stage of leukaemia at which the transplant was undertaken and the type of leukaemia. Relapse is generally assumed to occur in residual host cells, which are refractory to, or escape from the myeloablative conditioning therapy. Rare cases have been described, however, in which the leukaemia recurs in cells of donor origin. Lack of a successful outcome of blood or bone marrow transplantation for severe aplastic anaemia (SAA), however, is due to late graft rejection or graftversus-host disease. Leukaemia in cells of donor origin has rarely been reported in patients following allogeneic bone marrow transplantation for SAA. This report describes leukaemic transformation in donor cells following a second allogeneic BMT for severe aplastic anaemia. PCR of short tandem repeats in bone marrow aspirates and in colonies derived from BFUE and CFU-GM indicated the donor origin of leukaemia. Donor leukaemia is a rare event following transplantation for severe aplastic anaemia but may represent the persistence or perturbation of a stromal defect in these patients inducing leukaemic change in donor haemopoietic stem cells.
(GVHD, acute or chronic). 2 A rare complication following BMT for SAA is the development of acute leukaemia. Cytogenetic or DNA analysis has shown that in these rare cases, the leukaemia originates in host cells. 3 We previously reported the first case of a patient who developed acute monoblastic leukaemia in donor cells following BMT for SAA. 4 We now report a second case of donor cell leukaemia following BMT for SAA. Short tandem repeat PCR indicated complete donor haemopoiesis at the time of leukaemia development in a patient receiving a second BMT for SAA.
Patient and methods

Patient details
UPN 59 was a 12-year-old girl who presented with features of SAA at the Ospedale San Geraldo Monza in May 1991 with haemoglobin (Hb) of 6.7 g/dl, a white blood cell count (WBC) of 3.0 × 10 9 /l, and platelets of 66 × 10 9 /l. DEB was negative. Initial treatment was with cyclosporin (CsA) (5 mg/kg/day) for 4 months with no clinical response. She received an HLA-identical BMT from her sister in October 1991. Conditioning consisted of cyclophosphamide (200 mg/kg) and she was randomised to receive CsA as part of the European Blood and Marrow Transplant (EBMT) study on GVHD prophylaxis following allogeneic BMT for SAA. The number of cells infused was 2.7 × 10 8 /kg. Trilineage engraftment was observed at day 18 but the patient showed late graft failure at day 70 post BMT. A second BMT was undertaken using the same donor in late January 1992. On this occasion the conditioning regimen consisted of antilymphocyte globulin (ALG), cyclophosphamide (Cy) 150 mg/kg and thoraco-abdominal irradiation (6.0 Gy). The number of cells infused was 3.8 × 10 8 /kg. CsA was again given as GVHD prophylaxis. Engraftment was observed by day 13 post BMT. There was no evidence of acute GVHD. The patient remained transfusion independent from days 25-80 post BMT. At this time, her Hb levels were 6.9 g/dl and she required transfusion support. Her platelet count decreased again to less than 20 × 10 9 /l and on day 172 she was given a course of ATG (1.5 vials/10 kg for 5 days) in an effort to prevent graft failure. Her platelet levels rose but she developed what initially was believed to be serum sickness (arthralgias poorly responsive to steroids). However, a bone marrow (BM) aspirate at this time indicated acute myeloid leukaemia (AML M0 FAB) with 28% blasts present. She received intensive chemotherapy consisting of idarubicin (10 mg/m 2 /day for 3 days and ara-C 300 mg/m 2 /day for 7 days) in an effort to achieve remission but showed evidence of leukaemic progression and died of her disease on day 310 post second BMT.
Molecular studies
Bone marrow (BM) or peripheral blood (PB) was collected from donor and recipient pre-transplant to allow polymorphisms to be established for post-transplant study of haemopoietic chimaerism. DNA was prepared as previously described and subjected to PCR using a panel of short tandem repeat markers.
5, 6 Informative polymorphisms were established and used to follow post-transplant samples in a prospective fashion. In addition, short-term cultures of marrow taken at various time points were subjected to colony PCR. PCR primers and conditions for STR-PCR were as previously described. 5, 6 CFU-GM colonies and BFU-E colonies were grown from the patient at varying times post BMT (see Figures 1  and 2 ) and subjected to STR-PCR using appropriate polymorphic STRs. BM cells were separated on FicollHypaque density gradients and plated in Iscove's modified Dulbecco's medium (IMDM) supplemented with 20% fetal calf serum at a density of 10 5 cells/ml. After a 14 day incubation, colonies were scored under an inverted microscope and plucked for molecular analysis.
Results
Chimaerism studies were performed using STR markers and results are shown in Figures 1 and 2 . Initial evidence of a mixed haemopoietic profile was followed by a period of complete donor chimaerism as judged by PCR analysis of peripheral blood or CFU-GM colonies. Subsequently, there was a re-emergence of a substantial proportion of recipient cells on day 149 post BMT which coincided with a period of pancytopaenia. Analysis of CFU-GM colonies at this time revealed a complete donor profile in four of six colonies tested, but PCR of BFU-E colonies showed the appearance of a significant percentage of recipient cells (Figures 1 and 2 ). Subsequent treatment with ATG resulted in a restoration of donor haemopoiesis in both PB and CFU-GM colonies and PCR analysis continued to indicate complete donor haemopoiesis until the patient died on day 310 post BMT. The donor remains well 9 years following the original transplant.
Discussion
DNA polymorphisms are frequently used to assess haemopoietic chimaerism following allogeneic BMT for leukaemia or non-malignant haematological disorders. 7 In patients transplanted for leukaemia it is usually assumed that leukaemic relapse occurs in recipient cells following BMT and reflects re-emergence of resistant malignant cells from the original leukaemic clone or from clonal evoluation. In cases where no leukaemic marker is available, the appearance of recipient cells post BMT can be used as indirect evidence of leukaemic relapse. [7] [8] [9] However, recently the use of cytogenetics or molecular techniques has indicated that leukaemic relapse can occur in donor cells. The majority of these cases involve patients transplanted for acute leukaemia. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] (Table 1) , but five cases have been reported following BMT for chronic myeloid leukaemia [19] [20] [21] [22] [23] [24] and a single case following BMT for thalassaemia. 25 We previously reported the case of a patient in whom donor AML occurred after transplantation for SAA. 4 This case involved a 19-year-old man who received an HLA-identical BMT from his female cousin, having previously failed to respond to ATG, either alone or in combination with oxymetholone and cyclosporine. Trilineage engraftment was observed on day 28 post BMT and while there was early evidence of low-level mixed chimaerism (Ͻ5% recipient cells), the patient then reverted to a complete donor chimaerism after day 122 post BMT. However, 9 months post BMT, progressive thrombocytopenia was observed and BM smears taken at this time showed an infiltrate of blast cells. Cytogenetic analysis of a bone marrow aspirate, taken on day 319 post BMT indicated a translocation (t(9;11)(p22;q23)) in 20 of 20 metaphases tested, and all metaphases were 46, XX, (t(9;11)(p22;q23) indicat- ing that the aberrant karyotype (characteristic of AML M5) was present in female donor cells. STR-PCR confirmed the donor nature of the sample.
In the current case, leukaemic blasts were also detected in cells of donor origin and the timing of leukaemic transformation was also within the first year post transplant. While there was no chromosomal abnormality present and the donor and recipient were the same gender, the detection of complete donor chimaerism in both peripheral blood mononuclear cells and in CFU-GM, cultured from the patient both at the time of detection of blast cells and on several subsequent occasions, argues strongly for a case of donor cell leukaemia. STR-PCR is a highly sensitive technique, which in our hands routinely detects the minor cell population between 0.1 and 0.01%. 6 Thus the appearance of 30% blasts cells together with a complete donor profile with a highly sensitive PCR-based technique indicates that this is a second case of donor cell leukaemia following allogeneic BMT for SAA.
In this case we also demonstrated the origin of clonogenic erythroid and myeloid cells by STR-PCR. Several mechanisms have been postulated for the development of leukaemia in donor cells following allogeneic BMT. 21, 24 Examination of Figures 1 and 2 indicates that donor cell transformation can be an early or a late event. Mechanisms that have been postulated include the transfer of a gene with oncogeneic potential into a new environment, the possibility of a viral aetiology perhaps involving a dominant oncogene, the transformation of incoming donor cells by irradiation damaged residual recipient cells and a microenvironmental stromal defect which may support leukaemogenesis in the donor cells. However, the rarity with which donor cell leukaemia develops, particularly following BMT for SAA makes it difficult to support the thesis of a transmissible agent from patient stroma to donor stem Bone Marrow Transplantation cells as the underlying mechanisms for donor cell leukaemia.
While the search for a viral aetiology for human leukaemia has yielded little positive data although EBV may be implicated in the development of lymphoma, [26] [27] [28] one human leukaemia clearly has a retroviral origin. Acute T cell leukaemia is caused by the retrovirus HTLV 1. 29 This rare disease, which is seen predominantly in Japan and in the Caribbean, has occasionally been treated by allogeneic BMT. 30 We have previously reported a patient with HTLV 1 leukaemia who received a BMT from an HTLV 1 antibodynegative sibling. 31 Although the BMT was successful, the recipient subsequently died and HTLV 1 DNA was identified in lymphocytes, which were shown to be of donor origin by STR-PCR. This, therefore, is a clear example of the possibility of transfection of donor material following BMT with potentially 'leukemia inducing' retroviral material.
In the current case and our previously reported case, none of the mechanisms indicated above can satisfactorily explain leukaemic transfomation of donor cells following BMT for SAA. Chemotherapy-associated leukaemia usually has a longer latency period 29, 32 and cyclophosphamide treatment has not been associated with the development of leukaemia. 33 Recently, we have seen the occurrence of leukaemia in recipient cells in a patient transplanted for Fanconi anaemia in transformation, but this was detected almost 4 years post transplant. Socié et al 34 have commented on the increased risk of secondary malignancy following BMT for SAA where irradiation has been included in the conditioning regimen but the majority of these cases involve solid tumours of the head and neck and again the latency period is much longer than that seen in the current case. It remains a possibility that an intrinsic defect in recipient or donor marrow could have been activated by the use of irradiation in the second transplant, with the possibility of irradiation damaged cells contributing to the development of leukaemia. This case highlights the fact that donor cell leukaemia is a rare event but a potentially important entity in understanding the leukaemogenic process.
